CC BY-NC-ND 4.0 · Geburtshilfe Frauenheilkd 2019; 79(12): 1328-1335
DOI: 10.1055/a-1037-5205
GebFra Science
Review/Übersicht
Georg Thieme Verlag KG Stuttgart · New York

Treatment of Advanced Hormone Receptor-Positive (HR+) HER2-negative Breast Cancer

Article in several languages: English | deutsch
Nina Ditsch
1   Universitätsklinikum Augsburg, Brustzentrum, Klinik für Gynäkologie und Geburtshilfe, Augsburg, Germany
,
Marcus Schmidt
2   Klinik und Poliklinik für Geburtshilfe und Frauengesundheit der Johannes-Gutenberg-Universität Mainz, Mainz, Germany
› Author Affiliations
Further Information

Publication History

received 07 June 2019
revised 01 August 2019

accepted 29 October 2019

Publication Date:
11 December 2019 (online)

   Permissions and Reprints

Abstract

The article gives an overview of current treatment options for metastatic hormone receptor-positive and HER2-negative breast cancer. The focus is on combined therapies, e.g., with CDK4/6 inhibition compared with purely endocrine-based therapies in the pre- and postmenopause, presenting the latest study results. The addition of a CDK4/6 inhibitor to endocrine-based therapy with an aromatase inhibitor or fulvestrant leads to a marked improvement in progression-free survival and is independently beneficial whether palbociclib, ribociclib or abemaciclib is involved. The particular clinical status of inhibition of cyclin-dependent kinases argues for its use in the first-line treatment of women with metastatic, hormone receptor-positive and HER2-negative breast cancer compared with the available purely endocrine-based therapies.

Key words

breast cancer - metastasis - hormone receptor-positive - HER2-negative - CDK4/6 inhibitor
 

  • References/Literatur

  • 1 Ervik E, Lam F, Ferlay J. et al. Cancer Today. Lyon, France: International Agency for Research on Cancer; 2016. Online: http://gco.iarc.fr/today last access: 28.08.2019
    Google Scholar
  • 2 Blows FM, Driver KE, Schmidt MK. et al. Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies. PLoS Med 2010; 7: e1000279
    CrossrefPubMedGoogle Scholar
  • 3 Ibrahim T, Farolfi A, Scarpi E. et al. Hormonal receptor, human epeidermal growth factor-2, and Ki67 discordance between primary breast cancer and paired metastases: clinical impact. Oncology 2013; 84: 150-157
    CrossrefPubMedGoogle Scholar
  • 4 Lindström LS, Karlsson E, Wilking UM. et al. Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression. J Clin Oncol 2012; 30: 2601-2608
    CrossrefPubMedGoogle Scholar
  • 5 Rugo HS, Rumble RB, Macrae E. et al. Endocrine therapy for hormone-receptor-positive metastatic breast cancer. American Society of Clinical Oncology Guideline. J Clin Oncol 2016; 34: 3069-3103
    CrossrefPubMedGoogle Scholar
  • 6 Harbeck N, Gnant M. Breast Cancer. Lancet 2017; 389: 1134-1150
    CrossrefPubMedGoogle Scholar
  • 7 Bosseti C, Bertuccio P, Malvezzi M. et al. Cancer mortality in Europe, 2005–2009, and an overview of trends since 1980. Ann Oncol 2013; 24: 2657-2671
    CrossrefPubMedGoogle Scholar
  • 8 Jackisch C. Metastasiertes Mammakarzinom: Längeres und besseres Überleben. Dtsch Arztebl 2014; 111: 18
    Google Scholar
  • 9 Cardoso F, Senkus E, Costa A. et al. 4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)†. Ann Oncol 2018; 29: 1634-1657
    CrossrefPubMedGoogle Scholar
  • 10 Ettl J, Harbeck H. The safety and efficacy of palbociclib in the treatment of metastatic breast cancer. Expert Rev Anticancer Ther 2017; 17: 661-668
    CrossrefPubMedGoogle Scholar
  • 11 Reinert T, Barrios CH. Overall survival and progression-free survival with endocrine therapy for hormone receptor-positive, HER2-negative advanced breast cancer: review. Ther Adv Med Oncol 2017; 9: 693-709
    CrossrefPubMedGoogle Scholar
  • 12 Wöckel A, Festl J, Stüber T. et al. Interdisciplinary Screening, Diagnosis, Therapy and Follow-up of Breast Cancer. Guideline of the DGGG and the DKG (S3-Level, AWMF Registry Number 032/045OL, December 2017) – Part 1 with Recommendations for the Screening, Diagnosis and Therapy of Breast Cancer. Geburtsh Frauenheilk 2018; 78: 927-948 doi:10.1055/a-0646-4522
    Article in Thieme ConnectPubMedGoogle Scholar
  • 13 Thill M, Liedtke C, Müller V. et al. AGO Breast Committee. AGO Recommendations for the Diagnosis and Treatment of Patients with Advanced and Metastatic Breast Cancer: Update 2018. Breast Care (Basel) 2018; 13: 209-215 doi:10.1159/000489331
    CrossrefPubMedGoogle Scholar
  • 14 Sledge jr. GW, Hu P, Falkson G. et al. Comparison of chemotherapy with chemohormonal therapy as first-line therapy for metastatic, hormone-sensitive breast cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol 2000; 18: 262-266
    CrossrefPubMedGoogle Scholar
  • 15 Thill M, Schmidt M. Management of adverse events during cyclin-dependent kinase 4/6 (CDK4/6) inhibitor-based treatment in breast cancer. Ther Adv Med Oncol 2018; 10: 1758835918793326 doi:10.1177/1758835918793326
    CrossrefPubMedGoogle Scholar
  • 16 Robertson JFR, Bondarenko IM, Trishkina E. et al. Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial. Lancet 2016; 388: 2997-3005
    CrossrefPubMedGoogle Scholar
  • 17 Echavarria I, Jerez Y, Martin M. et al. Incorporating CDK4/6 Inhibitors in the Treatment of Advanced Luminal Breast Cancer. Breast Care (Basel) 2017; 12: 296-302
    CrossrefPubMedGoogle Scholar
  • 18 VanArsdale T, Bischoff C, Arndt KT. et al. Molecular pathways: targeting the cyclin D-CDK4/6 axis for cancer treatment. AACR Annual Meeting 2015. Clin Cancer Res 2015; 21: 2905-2910
    CrossrefPubMedGoogle Scholar
  • 19 Finn RS, Crown JP, Lang I. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet Oncol 2015; 16: 25-35
    CrossrefPubMedGoogle Scholar
  • 20 Loibl S, Turner NC, Ro J. et al. Palbociclib combined with fulvestrant in premenopausal women with advanced breast cancer and prior progression on endocrine therapy: PALOMA-3 results. Oncologist 2017; 22: 1028-1038
    CrossrefPubMedGoogle Scholar
  • 21 Turner NC, Slamon DC, Ro J. et al. Overall survival with Palbociclib and Fulvestrant in advanced breast cancer. N Engl J Med 2018; DOI: 10.1056/NEJMoa1810527.
    CrossrefPubMedGoogle Scholar
  • 22 Hortobagyi GN, Stemmer SM, Burris HA. et al. Ribociclib as first-line therapy for HR-positive, advanced breast cancer. N Engl J Med 2016; 375: 1738-1748
    CrossrefPubMedGoogle Scholar
  • 23 Slamon DJ, Neven P, Cjia S. et al. Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer. MONALEESA-3. J Clin Oncol 2018; 36: 2465-2472
    CrossrefPubMedGoogle Scholar
  • 24 Goetz MP, Toi M, Campone M. et al. MONARCH 3: Abemaciclib as initial therapy for advanced breast cancer. J Clin Oncol 2017; 35: 3638-3646
    CrossrefPubMedGoogle Scholar
  • 25 Sledge jr. GW, Toi M, Neven P. et al. MONARCH2: Abemaciclib in combination with fulvestrant in women with HR+/HER2-advanced breast cancer who had progressed while receiving endocrine therapy. J Clin Oncol 2017; 35: 2875-2884
    CrossrefPubMedGoogle Scholar
  • 26 Robertson JFR, Di Leo A, Fazal M. et al. Fulvestrant for hormone receptor-positive advanced breast cancer in patients with visceral versus non-visceral metastases: Findings from FALCON, FIRST and CONFIRM. San Antonio, TX: San Antonio Breast Cancer Symposium 2017: PD5-09.
    Google Scholar
  • 27 Bergh J, Jönsson PE, Lidbrink EK. et al. FACT: an open-label randomized phase III study of fulvestrant and anastrozole in combination compared with anastrozole alone as first-line therapy for patients with receptor-positive postmenopausal breast cancer. J Clin Oncol 2012; 30: 1919-1925 doi:10.1200/JCO.2011.38.1095
    CrossrefPubMedGoogle Scholar
  • 28 Mehta RS, Barlow WE, Albain KS. et al. Combination anastrozole and fulvestrant in metastatic breast cancer. N Engl J Med 2012; 367: 435-444 doi:10.1056/NEJMoa1201622
    CrossrefPubMedGoogle Scholar
  • 29 Finn RS, Martin M, Rugo HS. et al. Palbociclib and letrozole in advanced breast cancer. N Engl J Med 2016; 375: 1925-1936
    CrossrefPubMedGoogle Scholar
  • 30 Turner NC, Ro J, André F. et al. PALOMA3 Study Group. Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer. N Engl J Med 2015; 373: 209-219 doi:10.1056/NEJMoa1505270
    CrossrefPubMedGoogle Scholar
  • 31 Tripathy D, Im S, Colleoni M. et al. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial. Lancet Oncol 2018; 19: 904-915
    CrossrefPubMedGoogle Scholar
  • 32 Klijn JG, Blamey R, Boccardo F. et al. Combined hormone agents Trialists Group and the European Organization for Reasearch and Treatment of Cancer. Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials. J Clin Oncol 2001; 19: 343-353
    CrossrefPubMedGoogle Scholar
  • 33 Hurvitz SA, Im SA, Lu YS. et al. Phase III MONALEESA-7 trial of premenopausal patients with HR+/HER2− advanced breast cancer (ABC) treated with endocrine therapy ± ribociclib: overall survival (OS) results. J Clin Oncol 2019; 37 (Suppl.) Abstr.. LBA1008. doi:10.1200/JCO.2019.37.18_suppl.LBA1008
    CrossrefGoogle Scholar
  • 34 Lopez-Knowles E, OʼToole SA, McNeil CM. et al. PI3K pathway activation in breast cancer is associated with the basal-like phenotype and cancer specific mortality. Int J Cancer 2010; 126: 1121-1131
    CrossrefPubMedGoogle Scholar
  • 35 Bachelot T, Bourgier C, Cropet C. et al. Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study. J Clin Oncol 2012; 30: 2718-2724
    CrossrefPubMedGoogle Scholar
  • 36 Baselga J, Campone M, Piccart M. et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 2012; 366: 520-529
    CrossrefPubMedGoogle Scholar
  • 37 Early Breast Cancer Trialistsʼ Collaborative Group (EBCTCG). Davies C, Godwin J. et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 2011; 378: 771-784
    CrossrefPubMedGoogle Scholar
  • 38 Coleman RE, Bolten WW, Lansdown M. et al. Aromatase inhibitor-induced arthralgia: clinical experience and treatment recommendations. Cancer Treat Rev 2008; 34: 275-282
    CrossrefPubMedGoogle Scholar
  • 39 Dieras V, Rugo HS, Schnell P. et al. Long-term pooled safety analysis of Palbociclib in combination with endocrine therapy for HR+/HER2- advanced breast cancer. J Natl Cancer Inst 2018; DOI: 10.1093/jnci/djy109.
    CrossrefPubMedGoogle Scholar
  • 40 Durairaj C, Ruir-Garcia A, Gauthier ER. et al. Palbociclib has no clinically relevant effect on the QTc interval in patients with advanced breast cancer. Anticancer Drugs 2018; 29: 271-280
    CrossrefPubMedGoogle Scholar
  • 41 Tolaney SM, Lin NU, Thornton D. et al. Abemaciclib for the treatment of brain metastases (BM) secondary to hormone receptor positive (HR+), HER2 negative breast cancer. J Clin Oncol 2017; 35 (15 Suppl.): Abstr.. 1019
    CrossrefGoogle Scholar
  • 42 Park YH, Kim TY, Kim GM. et al. A randomized phase II study of palbociclib plus exemestane with GnRH agonist versus capecitabine in premenopausal women with hormone receptor-positive metastatic breast cancer (KCSG-BR 15-10, NCT02592746). J Clin Oncol 2019; 37: Abstr.. 1007
    CrossrefGoogle Scholar
  • 43 Lobbezoo DJ, van Kampen RJ, Voogd AC. et al. In real life, one-quarter of patients with hormone receptor-positive metastatic breast cancer receive chemotherapy as initial palliative therapy: a study of the Southeast Netherlands Breast Cancer Consortium. Ann Oncol 2016; 27: 256-262 doi:10.1093/annonc/mdv544
    CrossrefPubMedGoogle Scholar
  • 44 Kolberg H-C, Schneeweiss A, Fehm TN. et al. Update Breast Cancer 2019 Part 3 – Current Developments in Early Breast Cancer: Review and Critical Assessment by an International Expert Panel. Geburtsh Frauenheilk 2019; 79: 470-482
    Article in Thieme ConnectPubMedGoogle Scholar
  • 45 Wöckel A, Festl J, Stüber T. et al. Interdisciplinary Screening, Diagnosis, Therapy and Follow-up of Breast Cancer. Guideline of the DGGG and the DKG (S3-Level, AWMF Registry Number 032/045OL, December 2017) – Part 1 with Recommendations for the Screening, Diagnosis and Therapy of Breast Cancer. Geburtsh Frauenheilk 2018; 78: 927-948
    Article in Thieme ConnectPubMedGoogle Scholar